Login / Signup
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up.
Juliette Jacques
Nassim Sahki
Émilie Meknaci
Pascal Eschwege
Didier Peiffert
Nicolas Demogeot
Published in:
Brachytherapy (2024)
Exclusive BT is a long-term effective treatment for patients aged ≤ 60 years with low- or favorable intermediate-risk prostate adenocarcinoma.
Keyphrases
</>
prostate cancer
end stage renal disease
radical prostatectomy
ejection fraction
chronic kidney disease
squamous cell carcinoma
prognostic factors
low dose
combination therapy